{"name":"Akebia Therapeutics","slug":"akebia","ticker":"AKBA","exchange":"NASDAQ","domain":"akebia.com","description":"Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countri","hq":"Cambridge, MA","founded":2011,"employees":"194","ceo":"John P. Butler","sector":"Nephrology / Renal","stockPrice":1.17,"stockChange":-0.01,"stockChangePercent":-0.85,"marketCap":"$313M","metrics":{"revenue":232404000,"revenueGrowth":-6.6,"grossMargin":81.9,"rdSpend":62359000,"netIncome":-5345000,"cash":184844000,"dividendYield":0,"peRatio":-6.1,"fiscalYear":"FY2015"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"vadadustat patent cliff ($1.4B at risk)","drug":"vadadustat","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"vadadustat test tablets","genericName":"vadadustat test tablets","slug":"vadadustat-test-tablets","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"vadadustat test tablets","genericName":"vadadustat test tablets","slug":"vadadustat-test-tablets","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Akebia reported fourth quarter and full year 2023 financial results, with net product revenue of $13.4 million for the fourth quarter and $44.8 million for the full year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Akebia Therapeutics Announces Collaboration with Otsuka Pharmaceutical Co., Ltd. to Develop and Commercialize Vadadustat in Japan","summary":"Akebia announced a collaboration with Otsuka Pharmaceutical Co., Ltd. to develop and commercialize vadadustat in Japan.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Akebia Therapeutics Receives Complete Response Letter from FDA for Vadadustat New Drug Application","summary":"Akebia received a Complete Response Letter from the FDA for the vadadustat New Drug Application.","drugName":"","sentiment":"negative"}],"realNews":[{"date":"2026-04-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPRVpIcFFzSzlwQWQ3MjlhQzVCdW5rWGJfN0ZhZ2JRTUJpSkw5NjgzaVZpTDR6RDd4OE1wNFNxc0wtVTl0WF9SWk1lcTA2ekxoRk8zNUZRLUFiWnAtalZvYUhiQ1QxWFQ2dVItMnlYLVFjOXd1SURUSGdGRFo0dHgzMFUxS3RKLWJuQThJdHlsNkU1dXFMM3JqY3ZfUGw1UEFGNEdqVEJ2ZkNkUWNtYmxpa0IwTGVWMlJHd0E?oc=5","date":"2026-02-19","type":"pipeline","source":"Stock Titan","summary":"Akebia schedules Feb. 26 webcast on 2025 results, recent moves - Stock Titan","headline":"Akebia schedules Feb. 26 webcast on 2025 results, recent moves","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-16","type":"pipeline","source":"simplywall.st","summary":"In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st","headline":"In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNVkptaW9DNFNQMU83S0ZHeEgxYXJzbG56eEVnY1kxdV8wS092MEl1eFlDQV83RFgxRzdTUmI0cDNScnVmQm9MOXJ5SVBLSkNMQ3N2SlJyaUZNSzVZaVFlTDRUNFRkZzZaalJBdmphYkZLUVg3WXllWU9uTUx5VnVPVmduYzlKMmFrVmpZcERDRFFWeVZJeHAyVld1TVhGWFQxUkRTTlR2ZU5PcmhMUVdLTjdjRFB4amdLUWc?oc=5","date":"2025-12-20","type":"pipeline","source":"Trefis","summary":"How Low Can Akebia Therapeutics Stock Really Go? - Trefis","headline":"How Low Can Akebia Therapeutics Stock Really Go?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQRFd0Y2E2NlNBT1F5X044ZzkwRFo5RDlITGtVdWdrWFRfUlpqdVQzTGI1dWV2UGtOQVAzTEtRWXpRTTJLNzh1Y2NfM1FUdmNfMG9BWS1INExEYVJ4amFLb1h6R3VtWWh0dXN1ajlRMFloUEYtYWU5bHR5d09JTm95RUZQNzBkeTVuWTBCUUoxUDEyc05DVTB5Wlh1ZjcxTFF2czJRV3FR?oc=5","date":"2025-12-01","type":"earnings","source":"The Pharma Letter","summary":"Q32 Bio skyrockets as it sells complement inhibitor ADX-097 - The Pharma Letter","headline":"Q32 Bio skyrockets as it sells complement inhibitor ADX-097","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-04","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive - simplywall.st","headline":"Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxNOXdtUTFjMDdzc09wSXd0VVBWZWljRks0a0tpMGZWZi1EbV9rV3VERVdOR3RuZHFPY0E1WGpRbmRuNWc0ZlAwTERzLUExOGt6ZnI5MFN2YzdSbWdGUmxUdGlZTnoyTnlGcmFiVXhIalk1NHFQY09wZi05b0NoM2ZESFhwTmlJQ1RuajFMQjExYw?oc=5","date":"2025-10-15","type":"pipeline","source":"Yahoo Finance","summary":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics and Plus Therapeutics - Yahoo Finance","headline":"Zacks Industry Outlook Highlights Akebia Therapeutics, Ironwood Pharmaceuticals, Pyxis Oncology, Cardiol Therapeutics an","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-07","type":"earnings","source":"simplywall.st","summary":"Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook - simplywall.st","headline":"Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-10","type":"pipeline","source":"simplywall.st","summary":"Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st","headline":"Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNal9PbE5lakhoZWhSU19YME05QWJKbFFQRW02c00xYkxkcXdva3BmUmthQUhTUzZCMHY5N0Z1aGZ6dEhGWnRoaElySTNnLWdabDBhNzNROUNWRF8weGJKMW5hVlNscHlydXd3R09Bay1GVnh2X0ozQkhpMGNSbnRWV29CR1BxNlpmU2lOV3kyU3BMU3JzVHBjcjhLUmhUOHgweldDdXhOT1hvRVFKT2pYbG9RcUc0X1pt?oc=5","date":"2025-06-04","type":"earnings","source":"Seeking Alpha","summary":"Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha","headline":"Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPZGlMOEhsRmFZNXBqVWFHNDk3Z2ZWTUREbUR6cVhMbHFYUlhlZjdVd09TS1BYU1ZaRUNVZ0I3VTVOX2hyX0xYYTFVVTZUTTRUNmxtSmhROTN3TDlKWkkwV21abDlVRTZJMTJMTHI0QXFtamEyaDJVRkhENDlkRTkxbHRZSHBXeEZVZlpaUDhUOHVhTG1MYWRXY0M3YS1lYWJMZW0wTVc4TVRYSGc?oc=5","date":"2024-03-28","type":"regulatory","source":"reuters.com","summary":"U.S. FDA approves Akebia's anemia drug - reuters.com","headline":"U.S. FDA approves Akebia's anemia drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE44ZmFmQXFndWVqOEg2cUZ6cDgyVGZWY25ELTBVcjc5VFMwRmVGSFVtczVMM1AtRUgxaC1RaXo5bEtodjNRZ01TMEgwZk5PVHc4?oc=5","date":"2024-03-25","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQOXZDYVFGVE1QX01EcGZ5NjAzZnNVdGdxUDNuUGI5eEJ4SDZYTVV4SjRIaGdLRnA0c3VQS1Z6Qnp5RmNGVEpaZUl5RXFzamNfYWlER0JtOU80eDJkeWZYWmJkMk5vZmxRM29PQ3BkOTI1TmFhWkM2VnFqbUxRSk5TY0VWbVg2V0IzUXlRVU1fbElDcTVCekVDTml5akpTM1Y5d2RIR1hVcFhDUm9telB6Z0xoT1VuTFhHMk9Ba08tU1MzekhLdWxYTVB3?oc=5","date":"2021-06-01","type":"regulatory","source":"drugdiscoverytrends.com","summary":"FDA to review Akebia’s and Otsuka’s vadadustat for anemia resulting from chronic kidney disease - drugdiscoverytrends.com","headline":"FDA to review Akebia’s and Otsuka’s vadadustat for anemia resulting from chronic kidney disease","sentiment":"neutral"}],"patents":[{"drugName":"vadadustat","drugSlug":"vadadustat","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Fresenius Medical Care","DaVita Inc.","Keryx Biopharmaceuticals"],"therapeuticFocus":["Nephrology","Renal"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2015-12-31","revenueHistory":[{"value":0,"period":"2015-12-31"},{"value":0,"period":"2014-12-31"}],"grossProfit":196734000,"grossProfitHistory":[{"period":"2025-12-31","value":196734000},{"period":"2024-12-31","value":97003000},{"period":"2023-12-31","value":120474000},{"period":"2022-12-31","value":206916000}],"rdSpend":62359000,"rdSpendHistory":[{"period":"2025-12-31","value":62359000},{"period":"2024-12-31","value":37652000},{"period":"2023-12-31","value":63079000},{"period":"2022-12-31","value":129986000}],"sgaSpend":107480000,"operatingIncome":23499000,"operatingIncomeHistory":[{"period":"2025-12-31","value":23499000},{"period":"2024-12-31","value":-50414000},{"period":"2023-12-31","value":-46075000},{"period":"2022-12-31","value":-64846000}],"netIncome":-5345000,"netIncomeHistory":[{"period":"2025-12-31","value":-5345000},{"period":"2024-12-31","value":-69410000},{"period":"2023-12-31","value":-51925000},{"period":"2022-12-31","value":-94226000}],"eps":-0.02,"epsHistory":[{"period":"2025-12-31","value":-0.02},{"period":"2024-12-31","value":-0.33},{"period":"2023-12-31","value":-0.28},{"period":"2022-12-31","value":-0.51}],"cash":184844000,"cashHistory":[{"period":"2025-12-31","value":184844000},{"period":"2024-12-31","value":51870000},{"period":"2023-12-31","value":42925000},{"period":"2022-12-31","value":90466000}],"totalAssets":376565000,"totalLiabilities":343955000,"totalDebt":51798000,"equity":32610000,"operatingCashflow":67992000,"operatingCashflowHistory":[{"period":"2025-12-31","value":67992000},{"period":"2024-12-31","value":-40659000},{"period":"2023-12-31","value":-23384000},{"period":"2022-12-31","value":-73154000}],"capex":-8098000,"capexHistory":[{"period":"2025-12-31","value":-8098000},{"period":"2024-12-31","value":-33000},{"period":"2022-12-31","value":-114000},{"period":"2021-12-31","value":-59000}],"freeCashflow":59894000,"dividendsPaid":null,"buybacks":-1272000,"employees":194,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":26089000,"ebit":-6408000,"ebitda":-6087000,"period":"2025-12-31","revenue":57622000,"epsBasic":-0.05,"netIncome":-12244000,"rdExpense":26648000,"epsDiluted":-0.05,"grossProfit":45087000,"operatingIncome":-8553000},{"sga":29094000,"ebit":5903000,"ebitda":6221000,"period":"2025-09-30","revenue":58766000,"epsBasic":0,"netIncome":540000,"rdExpense":14944000,"epsDiluted":0,"grossProfit":49383000,"operatingIncome":4449000},{"sga":26555000,"ebit":7081000,"ebitda":7397000,"period":"2025-06-30","revenue":62472000,"epsBasic":0,"netIncome":247000,"rdExpense":11013000,"epsDiluted":0,"grossProfit":52553000,"operatingIncome":14089000},{"sga":25742000,"ebit":13882000,"ebitda":14196000,"period":"2025-03-31","revenue":57336000,"epsBasic":0.03,"netIncome":6112000,"rdExpense":9754000,"epsDiluted":0.03,"grossProfit":49711000,"operatingIncome":13514000},{"sga":27675000,"ebit":-15927000,"ebitda":-6582000,"period":"2024-12-31","revenue":46497000,"epsBasic":-0.1,"netIncome":-22804000,"rdExpense":11786000,"epsDiluted":-0.1,"grossProfit":26132000,"operatingIncome":-14307000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":1.17,"previousClose":1.18,"fiftyTwoWeekHigh":4.08,"fiftyTwoWeekLow":1.12,"fiftyTwoWeekRange":"1.125 - 4.079","fiftyDayAverage":1.38,"twoHundredDayAverage":2,"beta":0.35,"enterpriseValue":351424736,"forwardPE":-6.1,"priceToBook":11.42,"priceToSales":1.34,"enterpriseToRevenue":1.51,"enterpriseToEbitda":28.97,"pegRatio":0,"ebitda":12130000,"ebitdaMargin":5.2,"freeCashflow":65809876,"operatingCashflow":60372000,"totalDebt":197524000,"debtToEquity":721.5,"currentRatio":1.4,"returnOnAssets":2,"returnOnEquity":-79,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":5,"targetMeanPrice":4.2,"targetHighPrice":6,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4,"institutionHeldPercent":44.3,"sharesOutstanding":268258243,"floatShares":262584581,"sharesShort":27621774,"shortRatio":12.25,"shortPercentOfFloat":10.3,"epsTrailing":-0.08,"epsForward":-0.19,"revenuePerShare":0.88,"bookValue":0.1,"officers":[{"age":61,"name":"Mr. John P. Butler MBA","title":"CEO, President & Director"},{"age":53,"name":"Mr. Erik John Ostrowski M.B.A.","title":"Chief Business Officer, Senior VP, CFO & Treasurer"},{"age":64,"name":"Dr. Steven Keith Burke M.D.","title":"Senior VP and Chief Research & Development Officer"},{"age":55,"name":"Mr. Nicholas  Grund","title":"Senior VP & Chief Commercial Officer"},{"age":64,"name":"Mr. Richard C. Malabre","title":"Senior VP & Chief Accounting Officer"},{"age":null,"name":"Dr. Justin  McCue Ph.D.","title":"Senior VP & Chief Technology Officer"},{"age":null,"name":"Mercedes  Carrasco","title":"Senior Director of Investor & Corporate Communications"},{"age":44,"name":"Ms. Carolyn M. Rucci","title":"Senior VP, Chief Legal Officer & Secretary"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.akebia.com","phone":"617 871 2098"}}